Table of Contents
PRINCETON, N.J. — Ranbaxy Laboratories Inc. has announced the sales and promotion launch of Absorica capsules, a treatment for acne.
The company said Monday that its Absorica Capsules (isotretinoin) are licensed from Cipher Pharmaceuticals Inc.
Absorica is indicated to treat severe recalcitrant nodular acne in patients age 12 and older.
Ranbaxy noted that because of its high lipophilicity, oral absorption of isotretinoin is enhanced when given with a high-fat meal, but Absorica — formulated using patented Lidose technology — can be given without regard to meals.
"We are most pleased to make Absorica available as a valuable option for dermatologists and a subset of patients who suffer from severe recalcitrant nodular acne," stated Ashish Anvekar, senior director at Ranbaxy Laboratories Inc. "Absorica will be the flagship brand of the Ranbaxy dermatology product portfolio in the U.S."
